Sarilumab:A New Arsenal for Rheumatoid Arthritis
Journal Title: International Journal of Medical and Dental Sciences - Year 2017, Vol 6, Issue 2
Abstract
Rheumatoid arthritis is a debilitating disease that has significant impact on quality of life. Biological and non biological DMARDs improved the outcome in RA patients. New agents are still required in inadequate responders or intolerant patients. FDA has recently approved a new drug Sarilumab, a monoclonal antibody for the treatment of moderate to severe form of RA which acts by binding to Interleukin receptor 6 and interrupts the resultant cytokine-mediated inflammatory signaling.
Authors and Affiliations
Keywords
Related Articles
- EP ID EP482673
- DOI 10.19056/ijmdsjssmes/2017/v6i2/149923
- Views 75
- Downloads 0
Undetermined Teratogenic Risks by Traditional Sex Selection Drugs
Male child preference is a well known phenomenon in Indian society. There are various drugs and techniques used to achieve this target, even though these are illegal and punishable. Women desirous of male child try to pr...
Phenytoin beyond Epilepsy
No Abstract.
Plant Products in Dental and Periodontal Disease: An Overview
Dental diseases if left unchecked can lead to major health problems, on the other side periodontal diseases are recognized as a major public health problem throughout the world and is the most common cause of tooth loss...
Multiple calcified scrotal sebaceous cysts: A rare case presentation
A sebaceous cyst is a retention cyst. The classical management of scrotal sebaceous cysts is complete surgical excision and in the current era and as expected from the patient from the doctor and as the duty of the docto...
Cross Sectional Study of Health Profile of Interns of 2014 Batch of Terna Medical College, Nerul
Background: Health check-up of M.B.B.S. interns is not done routinely. They expose themselves to the hospital environment for a longer time than their student days. It results in a higher rate of contracting and transmit...